1. de Vries IJ, Adema GJ, Punt CJ, Figdor CG. Phenotypical and functional characterization of
clinical-grade dendritic cells. Methods Mol
Med, 2005. 109: 113-26.
2. Garcia-Parajo M, de Bakker BI, Koopman M, Cambi A, de Lange
F, Figdor CG, van Hulst NF. Near field
fluorenscence microscopy: an optical nanotool to study protein
organization at the cell membrane. J
Nanobiotech, 2005. 1: 113-20.
3. Meyer-Wentrup F, Cambi A, Adema GJ, Figdor CG. "Sweet talk": closing in on C type lectin
signaling. Immunity, 2005. 22(4): 399-400.
4. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines:
in vivo veritas?. Curr Opin Immunol, 2005.
17(2): 170-4.
5. Cambi A, Koopman M, Figdor CG. How C-type lectins detect pathogens.
Cell Microbiol, 2005. 7(4): 481-8.
6. van Beurden HE, Snoek PA, Von den Hoff JW, Torensma R, Maltha
JC, Kuijpers-Jagtman AM. Dynamic protein expression patterns during
intraoral wound healing in the rat. Eur J Oral
Sci, 2005. 113(2): 153-8.
7. Cambi A, Figdor CG. Levels of complexity in pathogen recognition by
C-type lectins. Curr Opin Immunol, 2005.
17(4): 345-51.
8. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP,
Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. Effective induction of naive and recall T-cell
responses by targeting antigen to human dendritic cells via a
humanized anti-DC-SIGN antibody. Blood, 2005.
106(4): 1278-85.
9. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM,
Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ.
Immunomonitoring tumor-specific T cells in
delayed-type hypersensitivity skin biopsies after dendritic cell
vaccination correlates with clinical outcome. J Clin
Oncol, 2005. 23(24): 5779-87.
10. Buckley CD, Halder S, Hardie D, Reynolds G, Torensma R, De
Villeroche VJ, Brouty-Boye D, Isacke CM. Report on antibodies submitted to the stromal cell
section of HLDA8. Cell Immunol, 2005.
236(1-2): 29-41.
11. Ossendorp F, Fu N, Camps M, Granucci F, Gobin SJ, van den
Elsen PJ, Schuurhuis D, Adema GJ, Lipford GB, Chiba T, Sijts A,
Kloetzel PM, Ricciardi-Castagnoli P, Melief CJ. Differential expression regulation of the alpha
and beta subunits of the PA28 proteasome activator in mature
dendritic cells. J Immunol, 2005. 174(12):
7815-22.
12. Eleveld-Trancikova D, Triantis V, Moulin V, Looman MW,
Wijers M, Fransen JA, Lemckert AA, Havenga MJ, Figdor CG, Janssen
RA, Adema GJ. The dendritic cell-derived protein DC-STAMP is
highly conserved and localizes to the endoplasmic reticulum.
J Leukoc Biol, 2005. 77(3): 337-43.
13. Radstake TR, van der Voort R, ten Brummelhuis M, de Waal
Malefijt M, Looman M, Figdor CG, van den Berg WB, Barrera P, Adema
GJ. Increased expression of CCL18, CCL19, and CCL17 by
dendritic cells from patients with rheumatoid arthritis, and
regulation by Fc gamma receptors. Ann Rheum
Dis, 2005. 64(3): 359-67.
14. van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH,
de Wilde PC, Balvers MG, Adema GJ, De Mulder PH. Intratumoral recombinant human interleukin-12
administration in head and neck squamous cell carcinoma patients
modifies locoregional lymph node architecture and induces natural
killer cell infiltration in the primary tumor. Clin
Cancer Res, 2005. 11(5): 1899-909.
15. van Herpen CM, Bussink J, van der Kogel AJ, Peeters WJ, van
der Voort R, van Schijndel A, de Wilde PC, Adema GJ, de Mulder PH.
Interleukin-12 has no effect on vascular density,
perfusion, hypoxia and proliferation of an implanted human squamous
cell carcinoma xenograft tumour despite up-regulation of
ICAM-1. Anticancer Res, 2005. 25(2A):
1015-21.
16. van der Voort R, van Lieshout AW, Toonen LW, Sloetjes AW,
van den Berg WB, Figdor CG, Radstake TR, Adema GJ. Elevated CXCL16 expression by synovial macrophages
recruits memory T cells into rheumatoid joints.
Arthritis Rheum, 2005. 52(5): 1381-91.
17. van der Voort R, Kramer M, Lindhout E, Torensma R, Eleveld
D, van Lieshout AW, Looman M, Ruers T, Radstake TR, Figdor CG,
Adema GJ. Novel monoclonal antibodies detect elevated levels
of the chemokine CCL18/DC-CK1 in serum and body fluids in
pathological conditions. J Leukoc Biol, 2005.
77(5): 739-47.
18. Netea MG, Ferwerda G, de Jong DJ, Jansen T, Jacobs L, Kramer
M, Naber TH, Drenth JP, Girardin SE, Kullberg BJ, Adema GJ, Van der
Meer JW. Nucleotide-binding oligomerization domain-2
modulates specific TLR pathways for the induction of cytokine
release. J Immunol, 2005. 174(10):
6518-23.
19. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van
Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema
GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in
melanoma patients for monitoring of cellular therapy.
Nat Biotechnol, 2005. 23(11): 1407-13.
20. Ferwerda G, Girardin SE, Kullberg BJ, Le Bourhis L, de Jong
DJ, Langenberg DM, van Crevel R, Adema GJ, Ottenhoff TH, Van der
Meer JW, Netea MG. NOD2 and toll-like receptors are nonredundant
recognition systems of Mycobacterium tuberculosis. PLoS
Pathog, 2005. 1(3): 279-85.
21. Radstake TR, van Lieshout AW, van Riel PL, van den Berg WB,
Adema GJ. Dendritic cells, Fc{gamma} receptors, and
Toll-like receptors: potential allies in the battle against
rheumatoid arthritis. Ann Rheum Dis, 2005.
64(11): 1532-8.
22. Netea MG, Van der Meer JW, Sutmuller RP, Adema GJ, Kullberg
BJ. From the Th1/Th2 paradigm towards a Toll-like
receptor/T-helper bias. Antimicrob Agents
Chemother, 2005. 49(10): 3991-6.
23. van Beurden HE, Von den Hoff JW, Torensma R, Maltha JC,
Kuijpers-Jagtman AM. Myofibroblasts in palatal wound healing: prospects
for the reduction of wound contraction after cleft palate
repair. J Dent Res, 2005. 84(10): 871-80.
24. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor
vaccination. Expert review of vaccines, 2005.
4(5): 699-710.
25. Torensma R. Blood vessels engineered from human cells.
Lancet, 2005. 366(9489): 892; author reply -3.